8-KEarnings & ResultsExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Jan 8, 2018)

Filed January 8, 2018For Securities:DXCM

Summary

DEXCOM INC (DXCM) announced preliminary, unaudited financial results for the fourth quarter and full fiscal year 2017, alongside an initial outlook for fiscal year 2018. The company reported strong year-over-year revenue growth, with Q4 2017 revenue expected to reach approximately $218 million, a 27% increase, and full-year 2017 revenue projected at $715 million, up 25%. This performance indicates continued positive momentum for DexCom. Looking ahead to fiscal year 2018, DexCom provided a revenue guidance range of $830 million to $850 million. Importantly, the company anticipates that growth in sensor volumes, international revenue, and its global patient base will outpace overall revenue growth, suggesting expanding market penetration and demand for its continuous glucose monitoring devices. Investors should note that these are preliminary figures subject to finalization and include forward-looking statements with associated risks and uncertainties.

Key Highlights

  • 1Preliminary Q4 2017 revenue estimated at $218 million, a 27% increase year-over-year.
  • 2Preliminary full-year 2017 revenue estimated at $715 million, a 25% increase year-over-year.
  • 3Initial fiscal year 2018 revenue outlook projected between $830 million and $850 million.
  • 4Expectation for 2018 sensor volume, international revenue, and patient base growth to exceed overall revenue growth.
  • 5Key information was shared during remarks at the J.P. Morgan 36th Annual Healthcare Conference.
  • 6The reported figures are preliminary and unaudited, subject to finalization in the upcoming 10-K filing.

Frequently Asked Questions

For the fourth quarter ended December 31, 2017, DexCom's preliminary, unaudited revenue was approximately $218 million, representing a 27% increase compared to Q4 2016. For the full fiscal year 2017, preliminary, unaudited revenue was expected to be $715 million, a 25% increase over 2016.

DexCom's initial financial outlook for fiscal year 2018 includes an estimated revenue range of $830 million to $850 million. Additionally, the company anticipates that growth in sensor volumes, international revenue, and its worldwide patient base will exceed its overall revenue growth for 2018.

No, the reported financial results are preliminary and unaudited. They are subject to finalization in connection with the preparation of DexCom's Annual Report on Form 10-K for the year ended December 31, 2017.

The information was presented at the J.P. Morgan 36th Annual Healthcare Conference and a webcast was available. The link to the webcast was available on DexCom's website (www.dexcom.com) by navigating to "About Us," then "Investor Relations," and then "Events and Presentations."